ViiV Healthcare
http://www.viivhealthcare.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ViiV Healthcare
ViiV Readies Entry To HIV PrEP Market After Apretude Approval
A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.
Merck & Co. Pauses Enrollment Of Oral Islatravir In PrEP Studies As Bad News Mounts
Merck has already paused other studies testing the potential first-in-class NRTTI and is adding additional monitoring of lymphocyte and CD4+ T-cell assessments.
GSK Looks To Long-Acting Therapy To Restore Lead In HIV
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.
ViiV & Janssen Win English Funding First For HIV Therapy
Around 13,000 people are now expected to be eligible for treatment with the long-acting, injectable Vocabria/Rekambys combination therapy in England.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals